Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Elif Şenocak TaşçıBaşak OyanÖzlem SönmezArda Ulaş MutluMuhammed Mustafa AtcıAbdullah Sakinİrem ÖnerHavva Yeşil ÇınkırMelek Karakurt EryılmazDilek ÇağlayanOnur Yazdan BalçıkNail PaksoySenem KarabulutDerya Kıvrak SalimCemil BilirMiraç ÖzenMelike ÖzçelikAli ArıcanBaran AkagündüzAli İnalDinçer AydınLeyla ÖzerAhmet GülmezNazım Serdar TurhalSelin Aktürk EsenEfnan AlgınSinem AkbaşYakup İriağaçTeoman ŞakalarÇağlar ÜnalÖzlem ErŞaban SeçmelerMustafa BozkurtPublished in: BMC cancer (2024)
Our study revealed that higher disease control and OS rates were achieved with rechallenge treatment compared to regorafenib, especially in patients who achieved disease control in one of the first two lines of therapy.